Analysts Maintain Buy Rating on Smith & Nephew Despite Slight Price Target Cut

Key Facts

In a move reflecting updated financial modeling within the healthcare sector, analysts have slightly adjusted their price expectations for Smith & Nephew. According to reports, the average 12-month price target was lowered from $36.31 to $35.96. Despite this adjustment, the analyst consensus remains firmly at a "Buy" rating, as the new target still implies a potential upside of 22% from recent closing levels.

This adjustment comes as the medical device sector faces mixed pressures, with investors closely monitoring peers such as Stryker and Zimmer Biomet. Per market data, a reduction of less than 1% is considered marginal and does not alter the long-term positive outlook for the company, particularly given the steady demand for orthopedic and reconstruction surgeries. Comparisons to the previous quarter suggest continued confidence in the company's ability to improve operating margins despite global logistics challenges.

Regarding price action, SNATS shares closed at levels reflecting a significant gap compared to analyst targets (close June 22, 2026). Traders should watch upcoming economic catalysts, including the UK CPI release on June 17, which could influence market sentiment for dual-listed entities in both London and New York.